Arctic Bioscience will publish a Q4 2023 operational update and preliminary full year 2023 financial results on Friday 1st of March, at
The same day at
Webcast details:
Date: Friday 1st of
Time:
Format: Webcast and Q&A
Language: English
The presentation can be accessed through the Company's website, or with the link below:
Link: https://channel.royalcast.com/landingpage/hegnarmedia/20240301_1/
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact:
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
Jone R. Slinning
CFO
Mobile: +47 948 75 469
E-mail: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.
https://news.cision.com/arctic-bioscience-as/r/arctic-bioscience---invitation-to-presentation-of-q4-2023-operational-update,c3933740
(c) 2024 Cision. All rights reserved., source